PDA (pentadeca arginate) looks new, but it really exists because BPC 157 got banned : r peptidebenchmark BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA Warning: Hidden Dangers of Smuggled Tirzepatide FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting FDA mulls compounding for peptides previously flagged over safety risks BioSpace The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing